Weiss Laurence, Ronsin Olivia, Reynaud Quitterie, Abely Michel, Mely Laurent, Burgel Pierre-Régis, Beltrand Jacques, Kessler Laurence
Pediatric Cystic Fibrosis Center, University Hospital of Strasbourg, France.
Adult Cystic Fibrosis Center, University Hospital Timone, Marseille, France.
J Clin Transl Endocrinol. 2022 Apr 4;28:100298. doi: 10.1016/j.jcte.2022.100298. eCollection 2022 Jun.
This study aimed to analyze clinical practices concerning cystic fibrosis-related diabetes (CFRD) screening in France. A web-based questionnaire was distributed between December 1, 2020 and January 31, 2021 among 47 cystic fibrosis centers including pediatric, adult, and mixed units. In accordance with guidelines, 92.8% of CF centers performed annual oral glucose tolerance tests (OGTT). Overall, 86.3% of CF centers performed 1- and 2-hour blood glucose determinations following OGTT. The OGTT was conducted before 10 years of age in 73% of pediatric centers. Continuous glucose monitoring (CGM) and laboratory glycated hemoglobin were employed for CFRD screening in 86.5% and 50% of centers, respectively. CGM was carried out in 69% of centers after glucose tolerance abnormalities had been detected in OGTT. Most CF centers used OGTT and CGM for CFRD screening. Studies are required to assess CGM usefulness as a validated tool in CFRD screening.
本研究旨在分析法国囊性纤维化相关糖尿病（CFRD）筛查的临床实践情况。2020年12月1日至2021年1月31日期间，通过网络问卷对47个囊性纤维化中心进行了调查，这些中心包括儿科、成人及混合科室。根据指南，92.8%的囊性纤维化中心进行年度口服葡萄糖耐量试验（OGTT）。总体而言，86.3%的囊性纤维化中心在OGTT后进行1小时和2小时血糖测定。73%的儿科中心在10岁之前进行OGTT。分别有86.5%和50%的中心采用持续葡萄糖监测（CGM）和实验室糖化血红蛋白进行CFRD筛查。在OGTT检测到糖耐量异常后，69%的中心进行了CGM。大多数囊性纤维化中心使用OGTT和CGM进行CFRD筛查。需要开展研究以评估CGM作为CFRD筛查有效工具的实用性。
